文献类型：期刊文献

中文题名：Association of anti-phospholipase A2 receptor antibody with the efficacy of traditional Chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a prospective, cohort clinical study

作者：Xian-Wen Zhang[1];Xiao-Xia Liu[2];Jun Yong[1];Li-Feng Wei[1];Chun-Yan Ling[1];Yu Jin[3];Yi-Ping Chen[1];Lin Wang[1]

机构：[1]Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;[2]Shanghai Minhang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai 200241,China;[3]Engineering Research Center of Pharmaceutical Engineering and Process Chemistry,Ministry of Education,School of Pharmacy,East China University of Science and Technology,Shanghai 200237,China

年份：2021

期号：18

起止页码：2252

中文期刊名：Chinese Medical Journal

外文期刊名：中华医学杂志（英文版）

收录：CSTPCD;;Scopus;CSCD:【CSCD2021_2022】；PubMed;

基金：supported by grants from the“3-Year Action Plan of Shanghai to Further Speed Up the Development of Traditional Chinese Medicine”(Nos.ZY[2018-2020]-FWTX-6025,ZY[2018-2020]-ZYBZ-02).

语种：英文

中文关键词：patients;Kidney;nephropathy;

摘要：To the Editor:Membranous nephropathy(MN)is an autoimmune disease and accounts for the most common cause of nephrotic syndrome in adults.In China,the incidence of MN is estimated at approximately 12/million per year,with a mean age between 50 and 60 years and a 2:1 male predominance.MN(29.1%)was the most common pathological disease in a 10-year renal biopsy analysis.[1]In 2019,the Kidney Diseases:Improving Global Outcomes(KDIGO)guidelines recognized anti-phospholipase A2 receptor(anti-PLA2R)autoantibodies as a valuable molecular risk factor for the pejorative evolution of kidney function and recommended monitoring them for the diagnosis and assessment of MN immune activity.Assessing circulating anti-PLA2R autoantibodies may help in monitoring disease activity and guiding personalized therapy in patients with primary MN.